ResearcherSağlık Bilimleri ÜniversitesiActive in the last 2 years

Abdullah Sakin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2538-8569; OpenAlex author ID A5089035885. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 4

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-026-47335-7 ↗
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-025-96157-6 ↗
Factors affecting survival in operated pancreatic cancer: Does tumor localization have a significant effect on treatment outcomes? Co-author DOI 10.14744/nci.2020.09735 ↗
Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis. Co-author PMID 33099936 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nargız Majidova · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Melike Özçelik · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
İlkay Gültürk · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Yasin Sezgin · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Bilgin Demir · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Yakup Ergün · 2 shared papers, 2025–2026 · strength 0.34
- Paper Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-026-47335-7 ↗
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Mustafa Yıldırım · 1 shared paper, 2025 · strength 0.16
- Paper Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. DOI 10.1038/s41598-025-96157-6 ↗
Şener Cihan · 1 shared paper, 2020 · strength 0.11
- Paper Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis. PMID 33099936 ↗
Ayşegül Sakin · 1 shared paper, 2020 · strength 0.11
- Paper Assessment of pretreatment albumin-bilirubin grade in pancreatic cancer patients with liver metastasis. PMID 33099936 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.